TABLE 1.
Clinical data of cohort under study
| Total cohort | ATTRwt | ATTRv | |
|---|---|---|---|
| Demographics | |||
| Male, n (%) | 28 (74%) | 17 (85%) | 11 (61%) |
| Female, n (%) | 10 (26%) | 3 (15%) | 7 (39%) |
| Age, years | 77 ± 7.7 | 80 ± 6.6 | 74 ± 7.8 |
| Ethnicity: African‐Caribbean, n (%) | 23 (61%) | 7 (35%) | 16 (89%) |
| Route of first contact, n (%) | |||
| Referral | 29 (76%) | 15 (75%) | 14 (78%) |
| NYHA class at symptom onset, n (%) | |||
| I | 7 (19%) | 3 (15%) | 4 (23%) |
| II | 21 (57%) | 9 (45%) | 12 (71%) |
| III | 5 (14%) | 4 (20%) | 1 (6%) |
| IV | 1 (3%) | 1 (5%) | 0 |
| NYHA class closest to diagnosis, n (%) | |||
| I | 5 (13%) | 4 (20%) | 1 (6%) |
| II | 15 (41%) | 5 (25%) | 10 (59%) |
| III | 10 (27%) | 8 (40%) | 2 (12%) |
| IV | 6 (16%) | 3 (15%) | 3 (17%) |
| Investigations | |||
| cMRI prior to diagnosis, n (%) | 32 (84%) | 16 (80%) | 15 (83%) |
| Biopsy | 28 (73%) | 15 (75%) | 12 (67%) |
| Medication use | |||
| ACE I or ARB | 29 (76%) | 15 (75%) | 14 (78%) |
| B Blocker | 31 (82%) | 17 (85%) | 14 (78%) |
| Diuretic | 34 (89%) | 17 (85%) | 17 (94%) |
| Mortality | |||
| 23 (61%) | 12 (60%) | 11 (61%) | |
Note: The data is presented as mean ± SD, n (%).
Abbreviations: ACE I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ATTRv, variant ATTR; ATTRwt, wild type ATTR; B Blocker, beta blocker; cMRI, cardiac magnetic resonance imaging; NYHA, New York Heart Association classification of heart failure.